About BIO-TECHNE (NASDAQ:TECH)
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, including cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment develops, manufactures, and sells tools, such as Biologics platform that enables researchers interrogate protein purity and identify contaminants during the development and production of biologics; Simple Western platform for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment offers controls and calibrators for hematology clinical instruments; blood chemistry and blood gas quality controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market; bulk purified proteins, enzymes, disease-state plasmas, infectious disease antigens, and processed serums to the clinical diagnostic industry; and Paratest, a novel and convenient stool collection and test device for the veterinary market. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
Trailing P/E Ratio47.89
Forward P/E Ratio40.41
Sales & Book Value
Annual Sales$563 million
Price / Sales10.92
Cash Flow$4.9887 per share
Price / Cash32.81
Book Value$25.44 per share
Price / Book6.43
EPS (Most Recent Fiscal Year)$3.42
Net Income$76.08 million
Return on Equity14.75%
Return on Assets9.35%
BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions
What is BIO-TECHNE's stock symbol?
BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."
How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?
BIO-TECHNE declared a quarterly dividend on Thursday, May 3rd. Investors of record on Monday, May 14th will be paid a dividend of $0.32 per share on Friday, May 25th. This represents a $1.28 annualized dividend and a yield of 0.78%. The ex-dividend date is Friday, May 11th. View BIO-TECHNE's Dividend History.
How were BIO-TECHNE's earnings last quarter?
BIO-TECHNE Corp (NASDAQ:TECH) issued its earnings results on Wednesday, May, 2nd. The biotechnology company reported $1.21 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.14 by $0.07. The biotechnology company earned $164 million during the quarter, compared to the consensus estimate of $163.43 million. BIO-TECHNE had a net margin of 18.29% and a return on equity of 14.75%. The business's quarterly revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 EPS. View BIO-TECHNE's Earnings History.
When is BIO-TECHNE's next earnings date?
What price target have analysts set for TECH?
7 equities research analysts have issued 12 month target prices for BIO-TECHNE's shares. Their forecasts range from $115.00 to $185.00. On average, they anticipate BIO-TECHNE's share price to reach $157.00 in the next year. View Analyst Ratings for BIO-TECHNE.
Who are some of BIO-TECHNE's key competitors?
Some companies that are related to BIO-TECHNE include NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), Ablynx (ABLYF), argenx (ARGX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), China Biologic Products (CBPO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA) and Repligen (RGEN).
Who are BIO-TECHNE's key executives?
BIO-TECHNE's management team includes the folowing people:
- Mr. Charles R. Kummeth, Pres, CEO & Director (Age 58)
- Mr. James T. Hippel, Sr. VP of Fin., CFO & Principal Accounting Officer (Age 47)
- Mr. N. David Eansor, Sr. VP of Biotechnology Division (Age 57)
- Mr. Robert M. Gavin, Sr. VP of Protein Platforms Division (Age 50)
- Mr. Kevin S. Gould, Sr. VP of Diagnostics Division (Age 52)
Has BIO-TECHNE been receiving favorable news coverage?
News headlines about TECH stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BIO-TECHNE earned a news sentiment score of 0.18 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.04 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are BIO-TECHNE's major shareholders?
BIO-TECHNE's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.83%), Atlanta Capital Management Co. L L C (5.11%), Neuberger Berman Group LLC (4.39%), Bamco Inc. NY (4.06%), Select Equity Group L.P. (1.75%) and Massachusetts Financial Services Co. MA (1.24%). Company insiders that own BIO-TECHNE stock include Charles A Dinarello, Charles R Kummeth, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for BIO-TECHNE.
Which major investors are selling BIO-TECHNE stock?
TECH stock was sold by a variety of institutional investors in the last quarter, including Select Equity Group L.P., Citadel Advisors LLC, New York State Common Retirement Fund, Sei Investments Co., Neuberger Berman Group LLC, Segall Bryant & Hamill LLC, Public Employees Retirement Association of Colorado and Russell Investments Group Ltd.. Company insiders that have sold BIO-TECHNE company stock in the last year include Charles A Dinarello, Charles R Kummeth, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for BIO-TECHNE.
Which major investors are buying BIO-TECHNE stock?
TECH stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, BlackRock Inc., Summit Trail Advisors LLC, Prudential Financial Inc., Schwab Charles Investment Management Inc., Asset Management One Co. Ltd., Citigroup Inc. and Mariner LLC. View Insider Buying and Selling for BIO-TECHNE.
How do I buy shares of BIO-TECHNE?
Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIO-TECHNE's stock price today?
One share of TECH stock can currently be purchased for approximately $163.68.
How big of a company is BIO-TECHNE?
BIO-TECHNE has a market capitalization of $6.22 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $3.42 on an earnings per share basis. BIO-TECHNE employs 1,800 workers across the globe.
How can I contact BIO-TECHNE?
BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]
MarketBeat Community Rating for BIO-TECHNE (TECH)MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.